Cardiovascular diseases have become a major clinical burden globally. Heart failure is one
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …

Heart failure is a serious threat to human health, with morbidity and mortality rates
increasing despite the existence of multiple treatment options. Therefore, it is necessary to …

Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …

LCZ696 (valsartan/sacubitril) has the potential to slow the progression of diabetic kidney
disease (DKD) according to previous reports. However, the renoprotective mechanism …

Aims Although right ventricular (RV) function is an important determinant of morbidity and
mortality in patients with pulmonary arterial hypertension (PAH), there is no treatment …

Aims Sacubitril/valsartan combines renin–angiotensin–aldosterone system inhibition with
amplification of natriuretic peptides. In addition to well‐described effects, natriuretic peptides …

Monoamine oxidases (MAOs), a class of enzymes bound to the outer mitochondrial
membrane, are important sources of reactive oxygen species. Increased MAO-A activity in …

Pulmonary vascular diseases (PVDs) have significant morbidity and mortality. Patients
present with either acute or chronic symptoms resulting from damage to the pulmonary …

Pulmonary hypertension (PH) is a progressive condition that affects the pulmonary vessels,
but its main prognostic factor is the right ventricle (RV) function. Many mice/rat models are …

Background Chronic obstructive pulmonary disease (COPD) is a common comorbidity in
heart failure with reduced ejection fraction, associated with undertreatment and worse …